{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:40:19Z","timestamp":1685925619677},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.imlet.2011.01.012","type":"journal-article","created":{"date-parts":[[2011,1,27]],"date-time":"2011-01-27T09:24:11Z","timestamp":1296120251000},"page":"213-220","source":"Crossref","is-referenced-by-count":1,"title":["Isolation of human Fab antibodies specific for the low-affinity IgE receptor (CD23) by selecting a hierarchical antibody library system against B lymphoblastic IM-9 cells"],"prefix":"10.1016","volume":"136","author":[{"given":"Hyo-jung","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suk-yoon","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-bong","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-kun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-hoon","family":"Cha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2011.01.012_bib0005","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.3816\/CLM.2006.s.002","article-title":"Treatment of non-Hodgkin's lymphoma: a look over the past decade","volume":"7","author":"Coiffier","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.imlet.2011.01.012_bib0010","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/asheducation-2009.1.440","article-title":"State-of-the-art treatment of chronic lymphocytic leukemia","author":"Hallek","year":"2009","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.imlet.2011.01.012_bib0015","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD 59 regulate complement-mediated cell lysis","volume":"95","author":"Golay","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2011.01.012_bib0020","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1182\/blood.V99.4.1314","article-title":"The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinasedependent mechanism","volume":"99","author":"Pedersen","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2011.01.012_bib0025","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ctrv.2007.08.003","article-title":"Recent progress in the management of chronic lymphocytic leukemia","volume":"33","author":"Robak","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.imlet.2011.01.012_bib0030","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1080\/1042819021000006547","article-title":"Results of first salvage therapy for patients refractory to a fludarabine regimer in chronic lymphocytic leukemia","volume":"43","author":"Keating","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.imlet.2011.01.012_bib0035","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2002-06-1639","article-title":"Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance","volume":"101","author":"ManShouri","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2011.01.012_bib0040","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.2005.04.021","article-title":"Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzuman therapy is associated with prolonged survival","volume":"23","author":"Moreton","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.imlet.2011.01.012_bib0045","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients repond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.imlet.2011.01.012_bib0050","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodkin's lymphoma: safety and efficacy of retreatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.imlet.2011.01.012_bib0055","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.2165\/11319270-000000000-00000","article-title":"Current and emerging treatments for chronic lymphocytic leukaemia","volume":"69","author":"Robak","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.imlet.2011.01.012_bib0060","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2174\/156800908783769319","article-title":"Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia","volume":"8","author":"Robak","year":"2008","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.imlet.2011.01.012_bib0065","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/asheducation-2007.1.233","article-title":"Monoclonal antibodies for B-cell lymphomas: rituximab and beyond","volume":"115","author":"Celeste Bello","year":"2007","journal-title":"Hematology"},{"key":"10.1016\/j.imlet.2011.01.012_bib0070","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0009-9120(02)00343-0","article-title":"Phage display technology: clinical applications and recent innovations","volume":"35","author":"Azzazy","year":"2002","journal-title":"Clin Biochem"},{"key":"10.1016\/j.imlet.2011.01.012_bib0075","first-page":"161","article-title":"Selection of human antibodies from phage display libraries","volume":"248","author":"Marks","year":"2004","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.imlet.2011.01.012_bib0080","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0167-5699(00)01667-4","article-title":"Natural and designer binding sites made by phage display technology","volume":"21","author":"Hoogenboom","year":"2000","journal-title":"Immunol Today"},{"key":"10.1016\/j.imlet.2011.01.012_bib0085","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2165\/00063030-200822050-00003","article-title":"Recombinant antibodies as therapeutic agents: pathways for modeling new biodrugs","volume":"22","author":"Aires da Silva","year":"2008","journal-title":"BioDrugs"},{"key":"10.1016\/j.imlet.2011.01.012_bib0090","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/nm1101-1249","article-title":"Biopanning and rapid analysis of selective interactive ligands","volume":"7","author":"Giordano","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.imlet.2011.01.012_bib0095","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.imlet.2010.08.009","article-title":"Isolation of a human anti-epidermal growth factor receptor Fab antibody EG-19-11, with subnanomolar affinity from na\u00efve immunoglobulin repertoires using a hierarchical antibody library system","volume":"134","author":"Hur","year":"2010","journal-title":"Immunol Lett"},{"key":"10.1016\/j.imlet.2011.01.012_bib0100","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.imlet.2010.05.002","article-title":"Development of the dual-vector system-III (DVS-III), which facilitates affinity maturation of a Fab antibody via light chain shuffling","volume":"132","author":"Hur","year":"2010","journal-title":"Immunol Lett"},{"key":"10.1016\/j.imlet.2011.01.012_bib0105","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jim.2007.11.015","article-title":"Establishment of a reliable dual-vector system for the phage display of antibody fragments","volume":"333","author":"Joo","year":"2008","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.imlet.2011.01.012_bib0110","unstructured":"Brian KK, Jill W, John MC. Phage display of peptides and proteins, a laboratory manual. San Diego: Acadimic Press, P107."},{"key":"10.1016\/j.imlet.2011.01.012_bib0115","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10059-009-0040-0","article-title":"Successful application of the dual-vector system II in creating reliable phage-displayed combinatorial Fab library","volume":"3","author":"Song","year":"2009","journal-title":"Mol Cells"},{"key":"10.1016\/j.imlet.2011.01.012_bib0120","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0022-1759(88)90196-2","article-title":"The measurement of relative antibody affinity by ELISA using thiocyanate elution","volume":"106","author":"Macdonald","year":"1988","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.imlet.2011.01.012_bib0125","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.bbrc.2008.11.129","article-title":"Isolation of antigen\/antibody complexes through organic solvent (ICOS) method","volume":"378","author":"Akahori","year":"2009","journal-title":"Biochem Biophy Res Commun"},{"key":"10.1016\/j.imlet.2011.01.012_bib0130","doi-asserted-by":"crossref","first-page":"31795","DOI":"10.1074\/jbc.273.48.31795","article-title":"Binding of anti-CD23 monoclonal antibody to the leucine zipper motif of FceRII\/CD23 on B cell membrane promotes its proteolytic cleavage: evidence for an effect on the oligomer\/monomer equilibrium","volume":"273","author":"Munoz","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.imlet.2011.01.012_bib0135","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.4049\/jimmunol.138.9.2970","article-title":"Produciton and characterization of a monoclonal antibody specific for the human lymphocyte low affinity receptor for IgE: CD 23 is a low affinity receptor for IgE","volume":"138","author":"Bonnefoy","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.imlet.2011.01.012_bib0140","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1172\/JCI115717","article-title":"CD23 antigen regulation and signaling in chronic lymphocytic leukemia","volume":"89","author":"Fournier","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.imlet.2011.01.012_bib0145","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0192-0561(99)00068-5","article-title":"In vitro IgE inhibition in B cells by anti-CD23 monoclonal antibodies is functionally dependent on the immunoglobulin Fc domain","volume":"22","author":"Nakamura","year":"2000","journal-title":"Int J Immunopharmacol"},{"key":"10.1016\/j.imlet.2011.01.012_bib0150","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.molimm.2004.03.040","article-title":"A high-affinity macaque antibody Fab with human-like framework regions obtained from a small phage display immune library","volume":"41","author":"Chassagne","year":"2004","journal-title":"Mol Immunol"},{"key":"10.1016\/j.imlet.2011.01.012_bib0155","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1158\/1078-0432.CCR-06-1463","article-title":"Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"13","author":"Byrd","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.imlet.2011.01.012_bib0160","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/blood-2007-03-082024","article-title":"Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines","volume":"111","author":"Pathan","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2011.01.012_bib0165","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1179\/102453309X446153","article-title":"Modern concepts in the treatment of chronic lymphocytic leukemia","volume":"14","author":"Smolej","year":"2009","journal-title":"Hematology"},{"key":"10.1016\/j.imlet.2011.01.012_bib0170","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2009-08-237727","article-title":"Phase 1\/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"115","author":"Byrd","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2011.01.012_bib0175","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/nbt0792-779","article-title":"By-passing immunization: building high affinity human antibodies by chain shuffling","volume":"10","author":"Marks","year":"1992","journal-title":"Biotechnology (NY)"},{"key":"10.1016\/j.imlet.2011.01.012_bib0180","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/9872","article-title":"Improving antibody affinity by mimicking somatic hypermutation in vitro","volume":"17","author":"Chowdhury","year":"1999","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.imlet.2011.01.012_bib0185","doi-asserted-by":"crossref","first-page":"726","DOI":"10.4161\/cbt.7.5.6097","article-title":"inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425","volume":"7","author":"Kamat","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.imlet.2011.01.012_bib0190","doi-asserted-by":"crossref","first-page":"35186","DOI":"10.1074\/jbc.M604127200","article-title":"PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting","volume":"281","author":"Kubetzko","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.imlet.2011.01.012_bib0195","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/intimm\/5.10.1251","article-title":"Maturation of human myelomonocytic leukemia cells following ligation of the low affinity receptor for IgE (Fc\u025bRII\/CD23)","volume":"5","author":"Ouaaz","year":"1993","journal-title":"Int Immunol"},{"key":"10.1016\/j.imlet.2011.01.012_bib0200","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0014-5793(02)02635-2","article-title":"Corticosteroid inhibits IL-4 signaling through down-regulation of IL-4 receptor and STAT6 activity","volume":"518","author":"So","year":"2002","journal-title":"FEBS Lett"},{"key":"10.1016\/j.imlet.2011.01.012_bib0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02686092","article-title":"Decoding IgE Fc receptors","volume":"37","author":"Zhang","year":"2007","journal-title":"Immunol Res"},{"key":"10.1016\/j.imlet.2011.01.012_bib0210","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jaci.2005.07.007","article-title":"Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects","volume":"116","author":"Poole","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.imlet.2011.01.012_bib0215","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0091-6749(03)01861-X","article-title":"Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial","volume":"112","author":"Rosenwasser","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.imlet.2011.01.012_bib0220","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1385\/CRIAI:29:1:061","article-title":"Anti-CD23","volume":"29","author":"Rosenwasser","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.imlet.2011.01.012_bib0225","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/hyb.1993.12.25","article-title":"Anti-CD23 monoclonal antibodies: comparisons of epitope specificities and modulating capacities for IgE binding and production","volume":"12","author":"Wakai","year":"1993","journal-title":"Hybridoma"},{"key":"10.1016\/j.imlet.2011.01.012_bib0230","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nri2273","article-title":"IgE in allergy and asthma today","volume":"8","author":"Gould","year":"2008","journal-title":"Nat Rev Immunol"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247811000332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247811000332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:13:51Z","timestamp":1685924031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247811000332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0165247811000332"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2011.01.012","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}